CureVac NV (CureVac NV) Price-to-Tangible-Book : 1.32 (As of May. 06, 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Price-to-Tangible-Book?

As of today (2024-05-06), CureVac NV's share price is $3.13. CureVac NV's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.38. Hence, CureVac NV's Price to Tangible Book Ratio of today is 1.32.

The historical rank and industry rank for CureVac NV's Price-to-Tangible-Book or its related term are showing as below:

CVAC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.32 Med: 5.32 Max: 17.25
Current: 1.32

During the past 6 years, CureVac NV's highest Price to Tangible Book Ratio was 17.25. The lowest was 1.32. And the median was 5.32.

CVAC's Price-to-Tangible-Book is ranked better than
76.84% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs CVAC: 1.32

A closely related ratio is called PB Ratio. As of today, CureVac NV's share price is $3.13. CureVac NV's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.52. Hence, CureVac NV's P/B Ratio of today is 1.24.

CureVac NV Price-to-Tangible-Book Historical Data

The historical data trend for CureVac NV's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Price-to-Tangible-Book Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

17.25

8.42

2.21

1.77

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															2.21	2.13	3.49	2.51	1.77

Competitive Comparison of CureVac NV's Price-to-Tangible-Book

For the Biotechnology subindustry, CureVac NV's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Tangible-Book falls into.

CureVac NV Price-to-Tangible-Book Calculation

CureVac NV's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	3.13	/	2.379
	=	1.32

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

CureVac NV Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of CureVac NV's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.